Kuo MT, et al. – In this study involving patients with chronic hepatitis B (CHB) without cirrhosis who discontinued entecavir (ETV) or tenofovir disoproxil fumarate (TDF), researchers compared hepatitis B virus (HBV) relapse rates. Study participants included 342 CHB patients (108 hepatitis B e antigen [HBeAg]-positive and 234 HBeAg-negative) who received ETV and 165 (46 HBeAg-positive, 119 HBeAg-negative) who received TDF. The results obtained from this retrospective-prospective study indicated that patients who stopped TDF had significantly higher rates of virological and clinical relapse earlier than those who stopped ETV. HBV relapse occurs earlier and is more severe after TDF cessation than after ETV cessation.